At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Brentuximab Vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy
In Brief
A Phase 4 clinical trial evaluating Brentuximab Vedotin for Hodgkin Lymphoma. Completed, enrolled 60 participants across 18 sites in 7 countries.
Detailed Summary
This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy and safety of brentuximab vedotin as a single agent in adult participants with histologically confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or multiagent chemotherapy at the time of study entry.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Lymphoma
CountriesCzechia, Germany, Malaysia, Poland, Spain, Thailand, Turkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartMar 2014
Primary CompletionMar 2016
Study CompletionMar 2020
TodayJul 2026
First PostedNov 21, 2013
Enrollment StartMar 14, 2014
Primary CompletionMar 24, 2016
Study CompletionMar 12, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.6 years ago
Interventions
Brentuximab Vedotindrug
Brentuximab vedotin IV infusion